Bortezomib Booms For Stada As Russian Problem Remains
Turnaround Strategy Is In The Works In Russia
With group sales rising by double digits in 2019, Stada says it has the firepower to accelerate investment not only in the firm’s own product development but also broadly into external co-development and product in-licensing, to support sustainability and long-term growth.
You may also be interested in...
Seven months after introducing its teriparatide biosimilar to Eli Lily’s Forsteo into many European markets, Stada is pleased with results and says doctors and patients alike have responded well.
Stada has announced the appointment of former Sandoz Germany head Stephan Eder to lead its business in Russia and the CIS. The appointment comes as Stada has just closed a $660m consumer healthcare acquisition with Takeda in the region.
Alvotech and Stada have struck a deal that will give Stada exclusive rights to sell seven Alvotech biosimilars “in all key European markets” as well as certain other territories.